R. Lazaro-Alcausi

Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC Study

M. Aresu, S. Chua, I. Chau, 2022, Current oncology.

SARS-CoV-2 Vaccine Immunogenicity in Patients with Gastrointestinal Cancer Receiving Systemic Anti-Cancer Therapy

S. Krishna, M. Aresu, H. Staines, 2022, The oncologist.

Clonal diversity of MYC amplification evaluated by fluorescent in situ hybridisation and digital droplet polymerase chain reaction in oesophagogastric cancer: Results from a prospective clinical trial screening programme.

A. Wotherspoon, D. Cunningham, C. Lord, 2019, European journal of cancer.

Perioperative FLOT plus anti-PD-L1 avelumab (FLOT-A) in resectable oesophagogastric adenocarcinoma (OGA): Interim safety analysis results from the ICONIC trial.

M. Gerlinger, D. Cunningham, Sacheen Kumar, 2021 .

Primary results of the ICONIC phase 2 trial of perioperative FLOT plus avelumab (FLOT-A) in operable oesophagogastric adenocarcinoma (OGA).

M. Gerlinger, S Kumar, I. Chau, 2023, Journal of Clinical Oncology.